OCD LIFU Target Engagement
Pilot Study to Investigate Brain Targets for Neuromodulation in Obsessive-compulsive Disorder
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Marshall Nambiar, MS
- 電話番号:215-746-8901
- メール:marshall.nambiar@pennmedicine.upenn.edu
研究場所
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- University of Pennsylvania
-
主任研究者:
- Katherine Scangos, MD, PhD
-
コンタクト:
- Marshall Nambiar, MS
- 電話番号:215-746-8901
- メール:marshall.nambiar@pennmedicine.upenn.edu
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
1. Participants must be enrolled in the IRB #853085 study
The inclusion criteria for the IRB #853085 study, which are also included in this trial are:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Adults aged 18-60 years old
- Chronic OCD (5 years preceding date of enrollment), diagnosed as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition guidelines (DSM-5)
- Presence of obsessions, compulsions, or both time-consuming obsessions and compulsions that take more than one hour a day or cause significant distress or impairment in social, occupation, or other important areas of functioning Obsessive-compulsive symptoms that are not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition
- Disturbance not better explained by the symptoms of another mental disorder listed in the DSM-5 Severe OCD symptoms, as defined by Y-BOCS I score of 28 or higher, within two weeks prior to enrollment
- Compulsions need to involve movement of the hands and/or arms so that the sleeve is able to detect participant's actions (cannot be solely mental or verbal compulsions)
- Ability to understand procedure-related instructions and to complete study assessments in English, and ability to comply with protocol requirements (e.g., procedure visits, treatment schedule, follow-up visit schedule, evaluations, etc.), in the opinion of the Principal Investigator
- Willingness and ability to provide written agreement to allow any and all forms of communication between the research team and treating clinician(s) 8 Willingness and ability to provide informed consent, in the opinion of the Principal Investigator
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Unable to undergo MRI scan
- Presence of metallic implants or devices or tattoos
- Claustrophobia or severe anxiety
- Inability to remain still for duration of scan
- Inability to fit and wear the ATTN201 device for the entire
Exclusion criteria for IRB study #853085 include:
- Hearing loss that, in the opinion of the Principal Investigator, an audiologist, or a treating physician, is likely to affect the subject's ability to comply with all of the requirements of the study, or may affect the integrity of the study data
- Pregnancy - this is an exclusion criterion because we will be intentionally increasing anxiety in participants to evaluate optimal strategies to provoke distress and then promote relaxation
- Any past or present medical condition, disease, disorder, or injury that, in the opinion of the Principal Investigator, may reduce or hinder the subject's ability to fully comply with all study requirements for the duration of the study or may impact, compromise, or affect the integrity of the data or results of the study.
- Have a previous injury or surgery which could affect the nerve distribution
- Have nerve damage (neuropathy)
- Have a diagnosed neuromuscular disorder
- Have a pacemaker
- Have a history of skin allergies, psoriasis eczema, dermatitis, or other skin inflammation conditions
- Compulsions cannot be completely mental or verbal actions, such as repeating words, counting objects, or performing mental rituals, and cannot involve only facial muscles/actions such as blinking or staring
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:LIFU Target Engagement Group
Participants in this single experimental group will undergo a series of low-intensity focused ultrasound (LIFU) sessions to evaluate safety and target engagement. Each participant will receive active LIFU stimulation at up to three personalized corticostriatal brain targets. The study utilizes a within-subject, sham-controlled design where participants receive both active LIFU and sham (placebo) stimulation across different sessions to compare physiological and clinical responses. |
Low-intensity focused ultrasound (LIFU) will be administered using the Attune ATTN201 device.
This intervention is characterized by a multifocal approach targeting three specific subcortical regions: the subthalamic nucleus (STN), the dorsal anterior cingulate cortex (dACC), and the ventral striatum (VS+).
Unlike clinical treatment trials, this is a target-engagement pilot study where each participant receives single sessions of sonication at these specific coordinates to evaluate acute physiological and symptomatic changes.
The intervention includes a within-subject sham-controlled component, where the device is positioned identically but no ultrasound energy is delivered.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Symptom Intensity through VAS score
時間枠:From the first visit (Visit 1) through the final visit (Visit 10), approximately 6 weeks.
|
This outcome evaluates the change in symptom intensity using Visual Analog Scales (VAS) scores.
VAS include questions regarding urges to compulse/resist compulsions and subjective units of distress (SUDs), measure the intensity of a patient's impulse to carry out or control and inhibit these compulsions, and the amount of distress they feel, and are on a scale between 0-100, where higher scores signify greater symptom severity.
|
From the first visit (Visit 1) through the final visit (Visit 10), approximately 6 weeks.
|
|
Changes in Imaging between Pre- and Post-Intervention
時間枠:Before the first visit (Visit 1) and after the final visit (Visit 10), approximately 6 weeks
|
This outcome measure evaluates safety and efficacy through neuroimaging conducted prior to and following the intervention.
These measures are intended to assess potential effects and target engagement associated with LIFU.
Efficacy measures will include changes in MRI-derived metrics (e.g., functional connectivity and/or regional activation in predefined regions of interest associated with the stimulation target).
Safety is assessed by the presence of new or worsening structural abnormalities, including edema, hemorrhage, or tissue injury.
|
Before the first visit (Visit 1) and after the final visit (Visit 10), approximately 6 weeks
|
|
Incidence of Adverse Events Assesed by Symptom Checklist
時間枠:Immediately after each intervention session and up to 24 hours post-intervention, assessed across the intervention period (Visits 6-9).
|
This outcome measure evaluates the incidence and severity of adverse events using a structured symptomatic checklist survey administered throughout the study period.
The checklist captures the presence, frequency, and severity of potential adverse symptoms.
Adverse events will be categorized by type, relatedness, and severity.
|
Immediately after each intervention session and up to 24 hours post-intervention, assessed across the intervention period (Visits 6-9).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Physiological Changes Measured by EMG
時間枠:Baseline through end of intervention period (Visits 2-9), with EMG data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in muscle activity using surface electromyography (EMG) recorded from the forearm during sessions.
EMG signals will be collected continuously and processed using standardized pipelines.
Metrics will include various features (e.g., SNR (dB)) over defined time windows.
Change in muscle activity will be assessed by comparing pre-sonication values to post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with EMG data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Y-BOCS score after sonication
時間枠:From the first baseline visit (Visit 1) through the final visit (Visit 10).
|
This outcome measures changes in Obsessive-Compulsive symptom severity using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), administered by a trained clinician.
Scores range from 0-40, with higher scores representing greater symptom severity.
|
From the first baseline visit (Visit 1) through the final visit (Visit 10).
|
|
Change in Acceleration Measured by IMU
時間枠:Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in forearm movement amplitude using inertial measurement unit (IMU)-derived acceleration data.
Acceleration (m/s²) will be recorded continuously from a microcontroller-based IMU placed on the participant's forearm during in-person sessions and processed using standardized signal processing pipelines.
Change in movement amplitude will be assessed by comparing pre-sonication and post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Angular Velocity Measured by IMU
時間枠:Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in forearm rotational movement using inertial measurement unit (IMU)-derived angular velocity data.
Angular velocity (°/s) will be recorded continuously from a microcontroller-based IMU placed on the participant's forearm during in-person sessions and processed using standardized signal processing pipelines.
Change in rotational movement will be assessed by comparing pre-sonication and post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Heart Rate Assessed by Photoplethysmography (PPG)
時間枠:Baseline through end of intervention period (Visits 2-9), with PPG data collected at every in-person visit, approximately 6 weeks.
|
This outcome evaluates changes in heart rate activity using photoplethysmography (PPG) recorded during sessions.
PPG signals will be collected from sensors placed on the participant and processed using standardized pipelines.
Changes in physiological response will be assessed by comparing pre to post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with PPG data collected at every in-person visit, approximately 6 weeks.
|
協力者と研究者
捜査官
- 主任研究者:Katherine Scangos, MD, PhD、University of Pennsylvania
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。